Symmetry Medical (SMA) Receives Coverage Optimism Rating of 0.19

Press coverage about Symmetry Medical (NYSE:SMA) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Symmetry Medical earned a news impact score of 0.19 on Accern’s scale. Accern also gave media stories about the healthcare company an impact score of 43.9944071978598 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/01/symmetry-medical-sma-receives-coverage-optimism-rating-of-0-19.html.

About Symmetry Medical

Symmetry Medical Inc (Symmetry) is a medical device solutions company, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company designs, develops and offers worldwide production and supply chain capabilities for these products to customers in the orthopedic industry, and other medical device markets (including but not limited to arthroscopy, dental, laparoscopy, osteobiologic, and endoscopy segments).

Insider Buying and Selling by Quarter for Symmetry Medical (NYSE:SMA)

Receive News & Ratings for Symmetry Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symmetry Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply